Facilitated By

San Antonio Medical Foundation

News

  • NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical ...

    ... the 2020 San Antonio Breast Cancer Symposium by Mario Lacouture, MD, Director of Oncodermatology, Memorial ... Opus Biotech Communications

  • Chinese drugmaker: Vaccine 79.3% effective in final tests

    Also Wednesday, Sinovac Biotech Ltd., signed an agreement to build a production facility in Beijing for a coronavirus vaccine with planned annual ...

  • Anixa Biosciences – Consensus Indicates Potential 207.0% Upside

    Anixa Biosciences has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy ...

  • Christmas morning explosion demonstrates how vulnerable cities are to bombings

    Professor of Biomedical Forensic Science at Boston University Dr. Adam Hall says, sadly, anyone can cause this kind of damage. “The surprising truth, ...

  • NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical ...

    INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY. SOURCE: NanOlogy. Copyright Business Wire 2020.